Discover
Off Script: A Pharma Manufacturing Podcast
FDA approves Opdivo subcutaneous version, Marinus Pharmaceuticals sells operations, Novo Nordisk pushes back against compounding pharmacies [The good, the bad, the ugly]
![FDA approves Opdivo subcutaneous version, Marinus Pharmaceuticals sells operations, Novo Nordisk pushes back against compounding pharmacies [The good, the bad, the ugly] FDA approves Opdivo subcutaneous version, Marinus Pharmaceuticals sells operations, Novo Nordisk pushes back against compounding pharmacies [The good, the bad, the ugly]](https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/b1/a9/59/b1a95912-60e7-b4e9-26f6-5f14abd60720/mza_16867596905298302268.jpg/400x400bb.jpg)
FDA approves Opdivo subcutaneous version, Marinus Pharmaceuticals sells operations, Novo Nordisk pushes back against compounding pharmacies [The good, the bad, the ugly]
Update: 2025-01-07
Share
Description
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:
The good — FDA approves Opdivo subcutaneous version
The bad — Marinus Pharmaceuticals sells operations
The ugly — Novo Nordisk pushes back against compounding pharmacies
Comments
In Channel
00:00
00:00
1.0x
0.5x
0.8x
1.0x
1.25x
1.5x
2.0x
3.0x
Sleep Timer
Off
End of Episode
5 Minutes
10 Minutes
15 Minutes
30 Minutes
45 Minutes
60 Minutes
120 Minutes
